VBS Shares Vectus Biosystems Limited
ASX · ASXLast in our picks 2026-10-13 — not in the current list; analysis below is from that screen
Fibrosis-focused biotechnology platform offers asymmetric upside if development milestones improve investor sentiment.
Future value: $0.18 (+71.43%) · 6-12 months
Signal breakdown
- ▸Early-stage pipeline provides optionality without strong confirmed momentum.
- ▾Below 50-day MA (-27.54%)
- ▸Volume 5.82× average — accumulation
- ▾Near 52-week low (8.1% of range)
- ▸~71% upside to price target
Is VBS a buy right now?
Trend: VBS is trading below the 50-day average (-30.77%), RSI 35 — neutral momentum, with a 3-month return of -30.77%.
Valuation & quality: Vectus Biosystems Limited trades on a trailing P/E of 3.0, price-to-book 2.37; fundamentals show net margin 56.3%, return on equity 139.3%, revenue growth 3169.1% year on year.
Our screen: BUY (score 2) — Fibrosis-focused biotechnology platform offers asymmetric upside if development milestones improve investor sentiment.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +7.10% | -20.00% | -8.30% | +18.20% | +0.00% | +46.20% | -42.10% | -18.20% |
Fundamentals
Technical signals
About Vectus Biosystems Limited
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.